Search
for
Sort by
Research 301–330 of 1000+
- High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
- Design and Characterization of Baricitinib Incorporated PLA 3D Printed Pills by Fused Deposition Modeling: An Oral Pill for Treating Alopecia Areata
- Alopecia Areata: Clinical Treatment
- Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey
- Molecular Mechanisms and Targeted Therapeutics in Androgenetic Alopecia: From Signaling Pathways to Regenerative Approaches
- Stem cell-based therapies for alopecia areata: a narrative review
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Intrinsic Modulators of Hair Growth: Roles of Growth Factors, Cytokines, Chemokines, and Interferons
- Associations between ionomic profile and metabolic abnormalities in a murine model of sodium sulfide induced alopecia areata
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- Baricitinib for the Treatment of Alopecia Areata
- Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response
- Review of Promising Off-Label Use of Deucravacitinib
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience